Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region.

Abstract

OBJECTIVE:

Appropriate monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with prophylactic antiemetics is important for cancer patients. This study was performed to validate the clinical practice of antiemetic use with carboplatin-based chemotherapy in lung cancer patients in the Hokushin region (Toyama, Ishikawa, Fukui, and Nagano prefectures), Japan.

METHODS:

We surveyed retrospective data of newly diagnosed and registered lung cancer patients initially treated with carboplatin-based chemotherapy in 21 principal hospitals in the Hokushin region linked with health insurance claims data between 2016 and 2017.

RESULTS:

A total of 1082 lung cancer patients (861 [79.6%] men, 221 [20.4%] women; median age 69.4 years [range, 33-89 years]). All patients received antiemetic therapy, with 613 (56.7%) and 469 patients (43.3%) receiving 5-hydroxytryptamine-3 receptor antagonist/dexamethasone double regimen and 5-hydroxytryptamine-3 receptor antagonist/dexamethasone/neurokinin-1 receptor antagonist triple regimen, respectively. However, the rates of double regimen and use of palonosetron were higher in Toyama and Fukui prefectures. Thirty-nine patients (3.6%) changed from double to triple regimen, while 41 patients (3.8%) changed from triple to double regimen after the second cycle, but six of these returned to triple antiemetics in subsequent cycles.

CONCLUSION:

Adherence to antiemetic guidelines in clinical practice was high in Hokushin region. However, rates of double and triple antiemetic regimens differed between the four prefectures. Simultaneous analysis of nationwide registry and insurance data was valuable for evaluating and comparing the differences in the status of antiemesis and management.

• Authors: Takayuki Ide, Yoshikazu Nishino, Tomoya Takiguchi, Shintaro Kanda, Kengo Otsuki, Ryuji Hayashi, Kazuo Yasumoto, Yasuo Hirono, Tomoe Makino, Seiji Yano, Tomonobu Koizumi
• Journal: BMC pulmonary medicine (BMC Pulm Med) Vol. 23 Issue 1 Pg. 228 (Jun 26 2023) ISSN: 1471-2466 [Electronic] England
• PMID: 37365528 (Publication Type: Multicenter Study, Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Antiemetics
• Carboplatin
• Receptors, Serotonin, 5-HT3
• Dexamethasone
• Antineoplastic Agents

Topics

• Male
• Humans
• Female
• Aged
• Antiemetics (therapeutic use, adverse effects)
• Carboplatin (therapeutic use, adverse effects)
• Retrospective Studies
• Receptors, Serotonin, 5-HT3 (therapeutic use)
• Dexamethasone (therapeutic use, adverse effects)
• Vomiting (chemically induced, drug therapy, prevention & control)
• Lung Neoplasms (drug therapy, etiology)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Antineoplastic Agents (adverse effects)